The Motley Fool··Jonathan PoncianoFirst Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns
First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge